Status:
COMPLETED
Safety Study of MGAH22 in HER2-positive Carcinomas
Lead Sponsor:
MacroGenics
Collaborating Sponsors:
Green Cross Corporation
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Gastric Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer. The study will also evaluate how long MGAH22 stays in the blo...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed carcinoma that overexpresses HER2 by immunohistochemistry (2+ or 3+ positivity by HercepTest or equivalent).
- Progressive disease during or after last treatment regimen.
- Appropriate treatment history for histological entity.
- ECOG Performance Status \<= 1.
- Life expectancy \>= 3 month.
- Measurable disease
- Acceptable laboratory parameters and adequate organ reserve.
- Baseline LVEF \>50%
Exclusion
- Lifetime anthracycline exposure \> 350 mg/m2 of doxorubicin or equivalent
- Major surgery within four weeks before enrollment.
- Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the drug formulation.
- Second primary malignancy that has not been in remission for greater than 3 years. Treated non-melanoma skin cancer, cervical carcinoma in situ on biopsy, or squamous intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score \< 6), or resected melanoma in situ are exceptions and do not require a 3 year remission.
- Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within four weeks of enrollment. Patients requiring any oral antiviral, fungal, or bacterial therapy must have completed treatment within one week of enrollment.
- History of chronic or recurrent infections that require continual use of antiviral, antifungal, or antibacterial agents.
- History of deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke within three months of enrollment.
- Known history of central nervous system (CNS) metastatic disease with evidence of residual or recurrent disease upon entry.
- New York Heart Association class III or IV heart disease.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 14 2022
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT01148849
Start Date
July 1 2010
End Date
June 14 2022
Last Update
February 26 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Bethesda, Maryland, United States, 20892
2
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
3
Seoul National University Hospital
Seoul, South Korea, 110-744